The News
Capital Coahuila
Capital Querétaro
Capital Edo. de Méx.
Capital México
Capital Mujer
Reporte Índigo
Estadio Deportes
The News
Efekto
Green TV
Revista Cambio
Digital
Prensa
Radio
TV

GlaxoSmithKline to spend $5.1B on cancer drugmaker Tesaro

By The News · 03 of December 2018 14:37:58
FILE- In this July 24, 2013, file photo a security guard walks in front of the GlaxoSmithKline building in Shanghai, China. Shares of Tesaro soared early Monday, Dec. 3, 2018, after GlaxoSmithKline said it would pay about $5.1 billion in cash to buy the cancer drugmaker. (AP Photo/Eugene Hoshiko, File), No available, FILE- In this July 24, 2013, file photo a security guard walks in front of the GlaxoSmithKline building in Shanghai, China. Shares of Tesaro soared early Monday, Dec. 3, 2018, after GlaxoSmithKline said it would pay about $5.1 billion in cash to buy the cancer drugmaker. (AP Photo/Eugene Hoshiko, File)

Shares of Tesaro soared Monday after GlaxoSmithKline said it would pay about $5.1 billion in cash to buy the cancer drugmaker.

Glaxo plans to pay $75 per share for Tesaro, which makes the ovarian cancer treatment Zejula. That represents a premium of more than 60 percent to the stock’s $46.38 closing price Friday. The total deal price includes Tesaro’s net debt.

Glaxo CEO Emma Walmsley said in a statement that the deal will accelerate growth of the British drugmaker’s oncology business.

Zejula brought in $166 million in revenue in the first nine months of this year, with third-quarter sales growing more than 60 percent.

Glaxo expects the deal to close in the first quarter.

Shares of Waltham, Massachusetts-based Tesaro Inc. jumped nearly 59 percent to $73.60 in morning trading.